BackgroundRegulatory agencies have been responsive to public demand for inclusion of the patient experience in evaluating and approving therapies. Over the years, patient-reported outcome measures (PROMs) have become increasingly prevalent in clinical trial protocols; however, their influence on regulators, payers, clinicians, and patients' decision-making is not always clear. We recently conducted a cross-sectional study aimed at investigating the use of PROMs in new regulatory approvals of drugs for neurological conditions between 2017 and 2022 in Europe.MethodsWe reviewed European Public Assessment Reports (EPARs) and recorded on a predefined data extraction form whether they considered PROMs, their characteristics (e.g., primary/secondary endpoint, generic/specific instrument) and other relevant information (e.g., therapeutic area, generic/biosimilar, orphan status). Results were tabulated and summarized by means of descriptive statistics.ResultsOf the 500 EPARs related to authorized medicines between January 2017 and December 2022, 42 (8%) concerned neurological indications. Among the EPARs of these products, 24 (57%) reported any use of PROMs, typically considered as secondary (38%) endpoints. In total, 100 PROMs were identified, of which the most common were the EQ-5D (9%), the SF-36 (6%), or its shorter adaptation SF-12, the PedsQL (4%).ConclusionsCompared to other disease areas, neurology is one where the use of patient-reported outcomes evidence is inherently part of the clinical evaluation and for which core outcome sets exist. Better harmonization of the instruments recommended for use would facilitate the consideration of PROMs at all stages in the drug development process.

Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022 / Ciani, Oriana; Meregaglia, Michela; Battaglia, Mario Alberto; Brichetto, Gianpaolo; Conte, Antonella; Gasperini, Claudio; Sansone, Valeria. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - (2023). [10.1007/s10072-023-06825-6]

Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022

Conte, Antonella;Gasperini, Claudio;
2023

Abstract

BackgroundRegulatory agencies have been responsive to public demand for inclusion of the patient experience in evaluating and approving therapies. Over the years, patient-reported outcome measures (PROMs) have become increasingly prevalent in clinical trial protocols; however, their influence on regulators, payers, clinicians, and patients' decision-making is not always clear. We recently conducted a cross-sectional study aimed at investigating the use of PROMs in new regulatory approvals of drugs for neurological conditions between 2017 and 2022 in Europe.MethodsWe reviewed European Public Assessment Reports (EPARs) and recorded on a predefined data extraction form whether they considered PROMs, their characteristics (e.g., primary/secondary endpoint, generic/specific instrument) and other relevant information (e.g., therapeutic area, generic/biosimilar, orphan status). Results were tabulated and summarized by means of descriptive statistics.ResultsOf the 500 EPARs related to authorized medicines between January 2017 and December 2022, 42 (8%) concerned neurological indications. Among the EPARs of these products, 24 (57%) reported any use of PROMs, typically considered as secondary (38%) endpoints. In total, 100 PROMs were identified, of which the most common were the EQ-5D (9%), the SF-36 (6%), or its shorter adaptation SF-12, the PedsQL (4%).ConclusionsCompared to other disease areas, neurology is one where the use of patient-reported outcomes evidence is inherently part of the clinical evaluation and for which core outcome sets exist. Better harmonization of the instruments recommended for use would facilitate the consideration of PROMs at all stages in the drug development process.
2023
European Medicines Agency; Patient-reported outcomes
01 Pubblicazione su rivista::01a Articolo in rivista
Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022 / Ciani, Oriana; Meregaglia, Michela; Battaglia, Mario Alberto; Brichetto, Gianpaolo; Conte, Antonella; Gasperini, Claudio; Sansone, Valeria. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - (2023). [10.1007/s10072-023-06825-6]
File allegati a questo prodotto
File Dimensione Formato  
s10072-023-06825-6.pdf

accesso aperto

Note: Ciani_Patient‑reported outcome measures_2023
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 592.53 kB
Formato Adobe PDF
592.53 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1683568
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact